NO20044533D0 - Fremgangsmate for fremstilling av 7-substituerte 3-kinolin og 3-kinol-4-onkarbonitriler - Google Patents

Fremgangsmate for fremstilling av 7-substituerte 3-kinolin og 3-kinol-4-onkarbonitriler

Info

Publication number
NO20044533D0
NO20044533D0 NO20044533A NO20044533A NO20044533D0 NO 20044533 D0 NO20044533 D0 NO 20044533D0 NO 20044533 A NO20044533 A NO 20044533A NO 20044533 A NO20044533 A NO 20044533A NO 20044533 D0 NO20044533 D0 NO 20044533D0
Authority
NO
Norway
Prior art keywords
oncarbonitriles
quinol
quinoline
substituted
preparation
Prior art date
Application number
NO20044533A
Other languages
English (en)
Other versions
NO20044533L (no
Inventor
Dan Maarten Berger
Diane Harris Boschelli
Yanong Daniel Wang
Steven Lawrence Johnson
Original Assignee
Wyeth Holdings Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Holdings Co filed Critical Wyeth Holdings Co
Publication of NO20044533D0 publication Critical patent/NO20044533D0/no
Publication of NO20044533L publication Critical patent/NO20044533L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
NO20044533A 2002-04-30 2004-10-21 Fremgangsmate for fremstilling av 7-substituerte 3-kinolin og 3-kinol-4-onkarbonitriler NO20044533L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37645602P 2002-04-30 2002-04-30
PCT/US2003/013149 WO2003093241A1 (en) 2002-04-30 2003-04-29 Process for the preparation of 7-substituted-3-quinoline and 3-quinol-4-one carbonitriles

Publications (2)

Publication Number Publication Date
NO20044533D0 true NO20044533D0 (no) 2004-10-21
NO20044533L NO20044533L (no) 2004-11-29

Family

ID=29401349

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20044533A NO20044533L (no) 2002-04-30 2004-10-21 Fremgangsmate for fremstilling av 7-substituerte 3-kinolin og 3-kinol-4-onkarbonitriler

Country Status (27)

Country Link
US (1) US6780996B2 (no)
EP (1) EP1499594B1 (no)
JP (1) JP2005529907A (no)
KR (1) KR20040106420A (no)
CN (1) CN100354263C (no)
AR (1) AR039776A1 (no)
AT (1) ATE302191T1 (no)
AU (1) AU2003231162B2 (no)
BR (1) BR0309712A (no)
CA (1) CA2483529A1 (no)
CO (1) CO5631435A2 (no)
CR (1) CR7511A (no)
DE (1) DE60301350T2 (no)
DK (1) DK1499594T3 (no)
EC (1) ECSP045406A (no)
ES (1) ES2243903T3 (no)
HK (1) HK1070358A1 (no)
IL (1) IL164851A0 (no)
MX (1) MXPA04010664A (no)
NO (1) NO20044533L (no)
NZ (1) NZ536141A (no)
RU (1) RU2309149C2 (no)
SI (1) SI1499594T1 (no)
TW (1) TWI275390B (no)
UA (1) UA77799C2 (no)
WO (1) WO2003093241A1 (no)
ZA (1) ZA200409639B (no)

Families Citing this family (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060167021A1 (en) * 2002-10-04 2006-07-27 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Inhibition of src for treatment of reperfusion injury related to revascularization
TW200423938A (en) * 2003-02-21 2004-11-16 Wyeth Corp 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolinecarbonitriles for the treatment of ischemic injury
SG146681A1 (en) * 2003-11-06 2008-10-30 Wyeth Corp 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml)
FR2862301B1 (fr) * 2003-11-17 2007-12-21 Aventis Pharma Sa Nouveau procede de preparation de quinoleines 3-fluorees
TW200529846A (en) * 2004-02-20 2005-09-16 Wyeth Corp 3-quinolinecarbonitrile protein kinase inhibitors
JP2008517924A (ja) * 2004-10-22 2008-05-29 ワイス 虚血傷害を処置するための４−［（２，４−ジクロロ−５−メトキシフェニル）アミノ］−６−アルコキシ−７−エチニル−３−キノリンカルボニトリル
CN102886045A (zh) 2005-02-03 2013-01-23 综合医院公司 治疗吉非替尼耐药性癌症的方法
CA2608540A1 (en) * 2005-05-18 2006-11-23 Wyeth 3-cyanoquinoline inhibitors of tpl2 kinase and methods of making and using the same
MX2007016230A (es) 2005-06-17 2008-03-06 Univ Texas Inhibicion de lesiones osteoliticas mediante inhibidores de quinasa src.
PL1902029T5 (pl) 2005-07-01 2022-08-29 Wyeth Llc Krystaliczne postacie 4-[(2,4-dichloro-5-metoksyfenylo)amino]-6-metoksy-7-[3(-4-metylo-1-piperazynylo)propoksy]-3-chinolino-karbonitrylu i sposoby ich wytwarzania
KR101354828B1 (ko) 2005-11-04 2014-02-18 와이어쓰 엘엘씨 ｍＴＯＲ 저해자, 헤르셉틴, 및/또는 ＨＫＩ-272의항신생물성 조합
TW200808728A (en) * 2006-05-23 2008-02-16 Wyeth Corp Method of preparing 4-halogenated quinoline intermediates
WO2008060283A1 (en) * 2006-11-16 2008-05-22 Wyeth 4-anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (aml)
US20080119463A1 (en) * 2006-11-16 2008-05-22 Wyeth 4-Anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (AML)
US11103497B2 (en) 2007-06-01 2021-08-31 Wyeth Llc Treatment of imatinib resistant leukemia
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
CN101602687A (zh) * 2008-06-13 2009-12-16 上海特化医药科技有限公司 6-硝基苯乙酮类化合物、其制备方法及用途
EP3135285B1 (en) 2008-06-17 2018-08-15 Wyeth LLC Antineoplastic combinations containing hki-272 and vinorelbine
EP2326329B1 (en) * 2008-08-04 2017-01-11 Wyeth LLC Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
WO2010030835A2 (en) * 2008-09-11 2010-03-18 Wyeth Llc Pharmaceutical compositions of an src kinase inhibitor and an aromatase inhibitor
CN101723854A (zh) 2008-10-24 2010-06-09 上海特化医药科技有限公司 6-取代氨基-3-氰基喹啉类化合物的制备方法及其中间体
DK3000467T3 (da) 2009-04-06 2023-03-27 Wyeth Llc Behandling med neratinib mod brystkræft
UY33236A (es) 2010-02-25 2011-09-30 Novartis Ag Inhibidores dimericos de las iap
WO2011153942A1 (zh) * 2010-06-09 2011-12-15 天津和美生物技术有限公司 氰基喹啉衍生物
UY33794A (es) 2010-12-13 2012-07-31 Novartis Ag Inhibidores diméricos de las iap
JP2014501235A (ja) 2010-12-13 2014-01-20 ノバルティス アーゲー 二量体ｉａｐ阻害剤
AU2012225735B2 (en) 2011-03-04 2016-03-10 Glaxosmithkline Intellectual Property Development Limited Amino-quinolines as kinase inhibitors
WO2013008217A1 (en) 2011-07-13 2013-01-17 Novartis Ag 4 - piperidinyl compounds for use as tankyrase inhibitors
CN103781776A (zh) 2011-07-13 2014-05-07 诺华股份有限公司 用作端锚聚合酶抑制剂的新的2-哌啶-1-基-乙酰胺化合物
US9227982B2 (en) 2011-07-13 2016-01-05 Novartis Ag 4-oxo-3,5,7,8-tetrahydro-4H-pyrano[4,3-d]pyrminidinyl compounds for use as tankyrase inhibitors
TWI547494B (zh) 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
US10023862B2 (en) 2012-01-09 2018-07-17 Arrowhead Pharmaceuticals, Inc. Organic compositions to treat beta-catenin-related diseases
TW201425307A (zh) * 2012-09-13 2014-07-01 Glaxosmithkline Llc 作為激酶抑制劑之胺基－喹啉類
AR092529A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
CN103804353A (zh) * 2012-11-01 2014-05-21 常辉 一类治疗精神分裂症的化合物及其用途
WO2014127214A1 (en) 2013-02-15 2014-08-21 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
HUE039052T2 (hu) 2013-02-19 2018-12-28 Novartis Ag Benzotiofénszármazékok és azok készítményei szelektív ösztrogén receptor lebontóként
AU2014219024B2 (en) 2013-02-20 2018-04-05 KALA BIO, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
ES2654100T3 (es) 2013-02-21 2018-02-12 Glaxosmithkline Intellectual Property Development Limited Quinazolinas como inhibidores de quinasa
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
MA38396B1 (fr) 2013-03-15 2019-05-31 Novartis Ag Anticorps medicamenteux conjugues et leurs compositions pharmaceutiques pour traiter un cancer positif a ckit
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
AU2014342042B2 (en) 2013-11-01 2017-08-17 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
WO2015092634A1 (en) 2013-12-16 2015-06-25 Novartis Ag 1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders
JP6473457B2 (ja) 2014-01-17 2019-02-20 ノバルティス アーゲー Ｓｈｐ２の活性を阻害するための１−（トリアジン−３−イル／ピリダジン−３−イル）−ピペリジン／ピペラジン誘導体およびその組成物
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
US10093646B2 (en) 2014-01-17 2018-10-09 Novartis Ag 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2
EP2980088A1 (en) 2014-07-28 2016-02-03 Bayer Pharma Aktiengesellschaft Amino-substituted isothiazoles
WO2015123758A1 (en) * 2014-02-20 2015-08-27 Apotex Inc. Bosutinib forms and preparation methods thereof
WO2015149727A1 (en) 2014-04-02 2015-10-08 Zentiva, K.S. Novel solid phases of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1 -piperazinyl)propoxy]-3-quinolinecarbonitrile
WO2016020791A1 (en) 2014-08-05 2016-02-11 Novartis Ag Ckit antibody drug conjugates
WO2016024195A1 (en) 2014-08-12 2016-02-18 Novartis Ag Anti-cdh6 antibody drug conjugates
EP3191126B1 (en) 2014-09-13 2020-05-13 Novartis AG Combination therapies of alk inhibitors
AU2015327868A1 (en) 2014-10-03 2017-04-20 Novartis Ag Combination therapies
CA2963935A1 (en) 2014-10-08 2016-04-14 Novartis Ag Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
CN104311485B (zh) * 2014-10-13 2016-08-24 烟台市华文欣欣医药科技有限公司 一种治疗白血病的药物博舒替尼的制备方法
EA201791050A1 (ru) 2014-11-14 2017-09-29 Новартис Аг Конъюгаты антител и лекарственных средств
WO2016100882A1 (en) 2014-12-19 2016-06-23 Novartis Ag Combination therapies
US20180000771A1 (en) 2015-01-13 2018-01-04 Kyoto University Agent for preventing and/or treating amyotrophic lateral sclerosis
CA2976766A1 (en) 2015-03-25 2016-09-29 Novartis Ag Formylated n-heterocyclic derivatives as fgfr4 inhibitors
WO2016168595A1 (en) 2015-04-17 2016-10-20 Barrett David Maxwell Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
US20190194315A1 (en) 2015-06-17 2019-06-27 Novartis Ag Antibody drug conjugates
WO2016203405A1 (en) 2015-06-19 2016-12-22 Novartis Ag Compounds and compositions for inhibiting the activity of shp2
CN112625028A (zh) 2015-06-19 2021-04-09 诺华股份有限公司 用于抑制shp2活性的化合物和组合物
EP3310779B1 (en) 2015-06-19 2019-05-08 Novartis AG Compounds and compositions for inhibiting the activity of shp2
US11747346B2 (en) 2015-09-03 2023-09-05 Novartis Ag Biomarkers predictive of cytokine release syndrome
CN105085398A (zh) * 2015-09-06 2015-11-25 合肥华方医药科技有限公司 一种博舒替尼异构体杂质的制备方法
MA44334A (fr) 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
JP6969800B2 (ja) 2016-05-04 2021-11-24 ジェノシアンス ファルマ 増殖性疾患の治療に使用される置換２，４−ジアミノ−キノリン誘導体
EA036446B1 (ru) 2016-06-14 2020-11-11 Новартис Аг Соединения и композиции для подавления активности shp2
US10392399B2 (en) 2016-09-08 2019-08-27 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CA3036336A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
BR112019004463A2 (pt) 2016-09-08 2019-05-28 Kala Pharmaceuticals Inc formas cristalinas de compostos terapêuticos, seus processos de obtenção e seus métodos de uso
WO2018067992A1 (en) 2016-10-07 2018-04-12 Novartis Ag Chimeric antigen receptors for the treatment of cancer
JOP20190187A1 (ar) 2017-02-03 2019-08-01 Novartis Ag مترافقات عقار جسم مضاد لـ ccr7
EP3592868B1 (en) 2017-03-06 2022-11-23 Novartis AG Methods of treatment of cancer with reduced ubb expression
WO2018185618A1 (en) 2017-04-03 2018-10-11 Novartis Ag Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
AR111651A1 (es) 2017-04-28 2019-08-07 Novartis Ag Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
WO2018215937A1 (en) 2017-05-24 2018-11-29 Novartis Ag Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
BR112019024556A2 (pt) 2017-05-24 2020-06-23 Novartis Ag Proteínas enxertadas com citocina de anticorpo e métodos para uso no tratamento de câncer
EP3630162A1 (en) 2017-05-24 2020-04-08 Novartis AG Antibody-cytokine engrafted proteins and methods of use
EP3681879A1 (en) 2017-09-11 2020-07-22 Krouzon Pharmaceuticals, Inc. Octahydrocyclopenta[c]pyrrole allosteric inhibitors of shp2
EP3788369A1 (en) 2018-05-01 2021-03-10 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
SG11202011872QA (en) 2018-07-10 2021-01-28 Novartis Ag 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of ikaros family zinc finger 2 (ikzf2)-dependent diseases
BR112021001148A2 (pt) 2018-07-25 2021-04-20 Advanced Accelerator Applications S.A. soluções estáveis de complexo de radionuclídeo concentrado
WO2020021465A1 (en) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) S.R.L. Method of treatment of neuroendocrine tumors
US11459340B2 (en) 2018-09-18 2022-10-04 Nikang Therapeutics, Inc. Tri-substituted heteroaryl derivatives as Src homology-2 phosphatase inhibitors
AU2019346550A1 (en) 2018-09-25 2021-04-22 Black Diamond Therapeutics, Inc. Quinazoline derivatives as tyrosine kinase inhibitor, compositions, methods of making them and their use
CN113164776A (zh) 2018-09-25 2021-07-23 黑钻治疗公司 酪氨酸激酶抑制剂组合物、其制备方法和使用方法
WO2020064693A1 (en) 2018-09-25 2020-04-02 Advanced Accelerator Applications (Italy) Srl Combination therapy
EP4282416A3 (en) 2018-09-29 2024-03-06 Novartis AG Process of manufacture of a compound for inhibiting the activity of shp2
EP3873532A1 (en) 2018-10-31 2021-09-08 Novartis AG Dc-sign antibody drug conjugates
SG11202104524YA (en) 2018-11-01 2021-05-28 Gracell Biotechnologies Shanghai Co Ltd Compositions and methods for t cell engineering
JP2022514315A (ja) 2018-12-20 2022-02-10 ノバルティス アーゲー ３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体を含む投与計画及び薬剤組み合わせ
JP2022515760A (ja) 2018-12-21 2022-02-22 ノバルティス アーゲー Ｐｍｅｌ１７に対する抗体及びその結合体
CA3124935A1 (en) 2019-02-15 2020-08-20 Novartis Ag 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
KR20210129672A (ko) 2019-02-15 2021-10-28 노파르티스 아게 치환된 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체 및 이의 용도
EP4007592A1 (en) 2019-08-02 2022-06-08 LanthioPep B.V. Angiotensin type 2 (at2) receptor agonists for use in the treatment of cancer
EP4013749A1 (en) 2019-08-15 2022-06-22 Black Diamond Therapeutics, Inc. Alkynyl quinazoline compounds
KR20220097418A (ko) 2019-11-01 2022-07-07 신젠타 크롭 프로텍션 아게 살충 활성 융합된 바이사이클릭 이종방향족 화합물
US11975026B2 (en) 2019-11-26 2024-05-07 Novartis Ag CD19 and CD22 chimeric antigen receptors and uses thereof
CN115052662A (zh) 2019-12-20 2022-09-13 诺华股份有限公司 抗TGFβ抗体和检查点抑制剂用于治疗增殖性疾病的用途
WO2021195206A1 (en) 2020-03-24 2021-09-30 Black Diamond Therapeutics, Inc. Polymorphic forms and related uses
US20230181756A1 (en) 2020-04-30 2023-06-15 Novartis Ag Ccr7 antibody drug conjugates for treating cancer
JP2023529211A (ja) 2020-06-11 2023-07-07 ノバルティス アーゲー Ｚｂｔｂ３２阻害剤及びその使用
JP2023531676A (ja) 2020-06-23 2023-07-25 ノバルティス アーゲー ３－（１－オキソイソインドリン－２－イル）ピぺリジン－２，６－ジオン誘導体を含む投与レジメン
CN116134027A (zh) 2020-08-03 2023-05-16 诺华股份有限公司 杂芳基取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
WO2022043557A1 (en) 2020-08-31 2022-03-03 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
WO2022043556A1 (en) 2020-08-31 2022-03-03 Novartis Ag Stable radiopharmaceutical composition
EP4204020A1 (en) 2020-08-31 2023-07-05 Advanced Accelerator Applications International S.A. Method of treating psma-expressing cancers
AU2021409561A1 (en) 2020-12-22 2023-07-06 Nikang Therapeutics, Inc. Compounds for degrading cyclin-dependent kinase 2 via ubiquitin proteosome pathway
CA3208313A1 (en) 2021-01-13 2022-07-21 Monte Rosa Therapeutics Ag Isoindolinone compounds
WO2022170052A1 (en) 2021-02-05 2022-08-11 Black Diamond Therapeutics, Inc. Quinazoline derivatives, pyridopyrimidine derivatives, pyrimidopyrimidine derivatives, and uses thereof
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
EP4323350A1 (en) 2021-04-14 2024-02-21 Monte Rosa Therapeutics AG Isoindolinone compounds
EP4323349A1 (en) 2021-04-14 2024-02-21 Monte Rosa Therapeutics AG Isoindolinone amide compounds useful to treat diseases associated with gspt1
WO2022221720A1 (en) 2021-04-16 2022-10-20 Novartis Ag Antibody drug conjugates and methods for making thereof
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
TW202307210A (zh) 2021-06-01 2023-02-16 瑞士商諾華公司 Ｃｄ１９和ｃｄ２２嵌合抗原受體及其用途
AU2022299145A1 (en) 2021-06-24 2023-12-07 Syngenta Crop Protection Ag 2-[3-[1 [(quinazolin-4-yl)amino]ethyl]pyrazin-2-yl]thiazole-5-carbonitrile derivatives and similar compounds as pesticides
WO2023284730A1 (en) 2021-07-14 2023-01-19 Nikang Therapeutics, Inc. Alkylidene derivatives as kras inhibitors
TW202346292A (zh) 2022-03-28 2023-12-01 美商尼坎醫療公司 作為週期蛋白依賴性激酶２抑制劑的磺醯胺基衍生物
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
WO2023240024A1 (en) 2022-06-08 2023-12-14 Nikang Therapeutics, Inc. Sulfamide derivatives as cyclin-dependent kinase 2 inhibitors
WO2023247360A1 (en) 2022-06-21 2023-12-28 Syngenta Crop Protection Ag Pesticidally active fused bicyclic heteroaromatic compounds
WO2024023666A1 (en) 2022-07-26 2024-02-01 Novartis Ag Crystalline forms of an akr1c3 dependent kars inhibitor
CN115286573A (zh) * 2022-08-04 2022-11-04 常州工程职业技术学院 一种1-烷氧基异喹啉化合物的绿色合成方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9756B (en) 1996-01-16 1997-07-17 Warner Lambert Co Process for preparing 4,6-disubstituted pyrido[3,4-d]-pyrimidines
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
UA73073C2 (uk) * 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
BR9914164A (pt) 1998-09-29 2001-06-26 American Cyanamid Co Composto, método para o tratamento, inibição do crescimento de, ou erradiacação de um neoplasma, e de doença de rim policìstico, em um mamìfero em necessidade do mesmo, composição farmacêutica, e, processo para preparar um composto
US6638929B2 (en) * 1999-12-29 2003-10-28 Wyeth Tricyclic protein kinase inhibitors
AR035851A1 (es) 2000-03-28 2004-07-21 Wyeth Corp 3-cianoquinolinas, 3-ciano-1,6-naftiridinas y 3-ciano-1,7-naftiridinas como inhibidoras de proteina quinasas
DE10017539A1 (de) 2000-04-08 2001-10-11 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbingungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
JP4326328B2 (ja) * 2001-07-16 2009-09-02 アストラゼネカ アクチボラグ キノリン誘導体及びそれらのチロシンキナーゼ阻害薬としての使用

Also Published As

Publication number Publication date
BR0309712A (pt) 2005-02-15
NZ536141A (en) 2006-03-31
CO5631435A2 (es) 2006-04-28
IL164851A0 (en) 2005-12-18
AU2003231162B2 (en) 2009-08-06
NO20044533L (no) 2004-11-29
DE60301350T2 (de) 2006-03-23
CA2483529A1 (en) 2003-11-13
ZA200409639B (en) 2006-06-28
US6780996B2 (en) 2004-08-24
WO2003093241A1 (en) 2003-11-13
ECSP045406A (es) 2005-01-03
UA77799C2 (en) 2007-01-15
KR20040106420A (ko) 2004-12-17
CN1665787A (zh) 2005-09-07
CR7511A (es) 2006-02-06
ATE302191T1 (de) 2005-09-15
EP1499594B1 (en) 2005-08-17
TWI275390B (en) 2007-03-11
US20030212276A1 (en) 2003-11-13
RU2004134735A (ru) 2005-06-10
JP2005529907A (ja) 2005-10-06
HK1070358A1 (en) 2005-06-17
CN100354263C (zh) 2007-12-12
DE60301350D1 (de) 2005-09-22
ES2243903T3 (es) 2005-12-01
SI1499594T1 (sl) 2005-12-31
AR039776A1 (es) 2005-03-02
DK1499594T3 (da) 2005-10-17
TW200306831A (en) 2003-12-01
AU2003231162A1 (en) 2003-11-17
RU2309149C2 (ru) 2007-10-27
MXPA04010664A (es) 2005-01-25
EP1499594A1 (en) 2005-01-26

Similar Documents

Publication Publication Date Title
NO20044533D0 (no) Fremgangsmate for fremstilling av 7-substituerte 3-kinolin og 3-kinol-4-onkarbonitriler
DK1542668T3 (da) Formulering af aripiprazolkompleks og fremgangsmåde
DK1667986T3 (da) Acetonesolvat af dimethoxydocetaxel og fremgangsmåde til fremstilling heraf
NO20040873L (no) Fremgangsmate og anordning for sammensetting av gjenfestbare absorberende klesplagg
NO20015547L (no) Fremgangsmåte for hemisyntese av forbindelser og nye forbindelser
NO20051493D0 (no) Imidazolpyridiner og fremgangsmater for fremstilling og anvendelse av de samme
NO20041975L (no) Bicyklisk oksopyridin og oksopyrimidinderivater
NO20022176D0 (no) Absorberende gjenstand og fremgangsmåte for fremstilling av denne
NO20033387D0 (no) Modifiserte antistoffer og fremgangsmåter for anvendelse
NO20053874D0 (no) Formulering og metoder for behandling av thrombocytemi
IS2654B (is) Essítalópram hýdróbrómíð og aðferð til framleiðslu þess
NO20033746D0 (no) Fremgangsmåte og blanding for syrebehandling av en underjordisk formasjon
NO20041004L (no) Fremgangsmate og anordning for sammensetting av gjenfestbare absorberende klesplagg
NO20033854D0 (no) N-but-3-enyl-norbuprenorfin og fremgangsmåter for anvendelse
NO20052859D0 (no) Fremgangsmate for fremstilling av resperidon og intermediater derav
NO20011026D0 (no) Matvare og fremgangsmÕte for fremstilling derav
DK1328538T3 (da) Fremgangsmåde og mellemprodukter til fremstilling af 7-substituerede antiöstrogener
NO20052188D0 (no) System og fremgangsmate for fremstilling av polysulfid
NO20030523D0 (no) Polymorfer av zaleplon og fremgangsmåter for fremstillingen derav
FI20010816A (fi) Menetelmä vastaanottimen tahdistamisessa ja vastaanotin
NO20033743L (no) Fremgangsmåte og fremstilling citalopram
NO20040346L (no) Ny krystall av aryletensulfonamid-derivat og fremstillingsprosess derav
NO20042126L (no) Syntese av 2-aralkoksyadenosiner og 2-alkoksyadenosiner
NO20044036L (no) Fremgangsmate for fremstilling av morfolinderivater og mellomprodukter derav
NO20025575D0 (no) Fremgangsmåte og innretning for produksjon av pölser

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application